ERNA (STOCKS)
Ernexa Therapeutics Inc. Common Stock
$0.199900
+0.004800 (+2.46%)
Prev close: $0.195100
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Sanjeev Luther
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $5.74M
- Employees
- 6
- P/E (TTM)
- -0.06
- P/B (TTM)
- 0.64
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | -$4.81M |
| Operating Expenses | $9.32M |
| Depreciation and Amortization | $100.00K |
| Other Operating Expenses | $9.22M |
| Operating Income/Loss | -$9.32M |
| Income/Loss From Continuing Operations After Tax | -$14.08M |
| Income/Loss From Continuing Operations Before Tax | -$14.13M |
| Income Tax Expense/Benefit | -$45.00K |
| Income Tax Expense/Benefit, Current | $3.00K |
| Income Tax Expense/Benefit, Deferred | -$48.00K |
| Net Income/Loss | -$14.08M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$14.08M |
| Net Income/Loss Available To Common Stockholders, Basic | -$14.10M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $16.00K |
| Preferred Stock Dividends And Other Adjustments | $16.00K |
| Basic Earnings Per Share | -$2.24 |
| Diluted Earnings Per Share | -$2.24 |
| Basic Average Shares | 6,307,000 |
| Diluted Average Shares | 6,307,000 |
| Assets | $5.83M |
| Current Assets | $3.13M |
| Noncurrent Assets | $2.70M |
| Fixed Assets | $94.00K |
| Other Non-current Assets | $2.61M |
| Liabilities | $3.43M |
| Current Liabilities | $3.11M |
| Accounts Payable | $1.13M |
| Wages | $12.00K |
| Other Current Liabilities | $1.98M |
| Noncurrent Liabilities | $320.00K |
| Equity | $2.40M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $2.40M |
| Liabilities And Equity | $5.83M |
| Net Cash Flow From Operating Activities | -$7.02M |
| Net Cash Flow From Operating Activities, Continuing | -$7.02M |
| Net Cash Flow From Investing Activities | -$37.00K |
| Net Cash Flow From Investing Activities, Continuing | -$37.00K |
| Net Cash Flow From Financing Activities | $7.21M |
| Net Cash Flow From Financing Activities, Continuing | $7.21M |
| Net Cash Flow | $155.00K |
| Net Cash Flow, Continuing | $155.00K |
| Comprehensive Income/Loss | -$14.08M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$14.08M |
| Other Comprehensive Income/Loss | $0.00 |